Almac Diagnostics Enters License Agreement with GeneGo

(St. Joseph, MI, USA), a leading provider of software, databases and services for systems biology, announced that Almac Diagnostics has licensed their flagship data mining suite, MetaCore.

The multiple-year agreement will allow Almac Diagnostics' scientists in the United Kingdom and the United States to use MetaCore in the development of novel microarray-based products for the diagnosis and treatment of cancer. Almac Diagnostics' Genomic Services division that delivers comprehensive genomic services to academic, biotech, and pharmaceutical customers will also use MetaCore. Almac values the completeness and quality of content coverage in MetaCore from signaling ligands to core metabolic pathways, its intuitive interface and comprehensive automated analysis workflows.

We compared several platforms before we finally decided on GeneGo. MetaCore has broad and deep, high quality content coverage, which was important to us. Furthermore, its ability to work with mixed IDs is critical for our internal R&D work and service offerings based on our unique digital services algorithm (DSA patent pending) research tools, said Dr. Vitali Proutski, bioinformatics manager at Almac Diagnostics.

Almac Diagnostics develops markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product.

Almac Diagnostics has two divisions: The Genomic Services division provides all- inclusive gene expression, single nucleotide polymorphism (SNP), and bioinformatics services to academia, biotech, and pharmaceutical companies.

GeneGo develops systems biotechnology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA, and other phenotypic data), and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biologic pathways and networks. GeneGo's flagship product, MetaCore 4.1, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug, is designed for prediction of human metabolism, toxicity, and biologic effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.



Related Links:
Almac Diagnostics
GeneGo